Compare Quest Diagnostics Inc (DGX) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Icl Group Ltd — how do they compare? Quest Diagnostics Inc trades at $204.9 (market cap $22.80B), while Icl Group Ltd trades at $5.06 (market cap $6.49B). The key difference: Quest Diagnostics Inc is far larger — about 3.5× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.8%). Which is the better fit depends on your goals.
| DGX | ICL | |
|---|---|---|
Market Cap | $22.80B | $6.49B |
Sector | Health | Basic Materials |
52-Week High | $216.02 | $7.03 |
52-Week Low | $166.42 | $4.80 |
Enterprise Value | $28.82B | $9.06B |
Dividend Yield | 1.67% | 3.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
ICL trades at $4.93, up 1.65% today, with a bearish technical signal and neutral oscillators. The company reported Q1 2026 EPS of $0.11, beating expectations, and maintains a dividend of $0.05. Revenue for 2025 was $7.15B with a net income margin of 3.52%, while valuation ratios like P/E of 23.48 and P/S of 0.86 suggest moderate pricing. Recent news highlights a $800M senior notes offering completed in June 2026.
Outlook is mixed: earnings beats and dividend yield offer support, but declining profit margins and bearish analyst consensus (100% hold) indicate caution. Key risks include raw material costs and forex headwinds, with institutional sentiment leaning neutral amid stable cash flows.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
